All articles tagged with #clinical trial results
Novo Nordisk’s next‑gen weight‑loss drug CagriSema failed to meet its primary endpoint in a late‑stage trial, delivering 23% average weight loss over 84 weeks versus 25.5% for Eli Lilly’s tirzepatide, prompting a sharp stock drop and renewed investor skepticism. The company plans a higher‑dose study and continues pursuing approval based on earlier data, while analysts noted the result as a setback for its obesity‑drug ambitions.
Summit Therapeutics' lung cancer drug ivonescimab shows promising results in China but weaker and non-significant benefits in North America and Europe, potentially complicating its approval process in Western markets due to geographic disparities in trial outcomes.
Viking Therapeutics stock experienced a volatile week following the announcement of positive phase II clinical trial results for its weight-loss drug, VK2735, causing shares to more than double on Tuesday. Despite a subsequent 15% drop after a stock offering, the stock has seen a 322% increase since the beginning of the year. The drug's impressive weight-loss results have sparked Wall Street's interest, with analysts raising peak sales estimates and suggesting that Viking could be an acquisition target for big pharmaceutical companies.